Strengthen the research of medication for the treatment of nontuberculous mycobacterial disease
10.3760/cma.j.issn.1674-2397.2023.03.003
- VernacularTitle:加强非结核分枝杆菌病治疗药物研究
- Author:
Jianqiong GUO
1
;
Yi FAN
;
Tongxin LI
;
Shenjie TANG
;
Song YANG
Author Information
1. 陆军军医大学第一附属医院感染病科，重庆 400038
- Keywords:
Nontuberculous mycobacteria;
Medication;
Research progress
- From:
Chinese Journal of Clinical Infectious Diseases
2023;16(3):174-182
- CountryChina
- Language:Chinese
-
Abstract:
The global trends of nontuberculous mycobacteria (NTM) infection and disease are both rising. Nontuberculous mycobacterial disease(NTMD) is a worldwide health burden associated with increasing morbidity, mortality, and economic costs. Antibiotic therapy is the mainstay of treatment for NTMD.Mycobacterial pathogens are intrinsically resistant to many available antibiotics, making treatment extremely challenging, especially in immunocompromised individuals and patients with underlying chronic lung conditions. Even with lengthy therapy and the use of a combination of antibiotics, only less than half NTMD patients can achieve clinical treatment success, so it is urgent to develop novel anti-NTM antibiotics. This article reviews the research progress on the medication of nontuberculous mycobacterial diseases.
